Latest Advances in Lung Cancer Research

Study finds NSCLC patients treated with low-dose radiation & immunotherapy had higher progression-free survival than with immunotherapy alone – combo extended PFS and bolstered immune response.

David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.

Changing the current lung cancer guidelines to a 2-year smoking duration cutoff vs a 20 pack-year cutoff would significantly improve the rate of cancer detection and reduce racial disparities with screenings.

LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints. Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression.

Artificial intelligence (AI) assessments of chest X-rays identified 28% of never-smokers as being at high-risk for lung cancer, according to research to be presented at the annual Radiological Society of North America (RSNA) conference.

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Recent studies confirm genomic testing for NSCLC enhances treatment choices and survival, advocating for its standardization in clinical practice.

Rising lung cancer in young, non-smoking women puzzles doctors; research on potential pregnancy link and new causes is crucial for prevention and early detection.

A novel nanoparticle vaccine halts lung cancer spread in mice by training the immune system to attack tumor cells, showing promise for post-surgery cancer prevention.

UCLA researchers received a $6 million grant to refine a liquid biopsy blood test for early, accurate lung cancer detection and treatment guidance.

Researchers developed a test detecting proteins in blood that indicate lung cancer spread, promising for early metastasis detection and treatment guidance.

Johnson & Johnson’s Rybrevant shows comparable efficacy to AstraZeneca’s Tagrisso in advanced NSCLC, suggesting potential as an initial treatment option.